Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study (vol 8, e002012, 2022)R. Fleischmann,E. Mysler,L. BessetteRMD OPEN（2023）引用 40|浏览1暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
